Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (NASDAQ: ALEC) is a late-stage clinical biotechnology company headquartered in South San Francisco, California, focused on therapies for neurodegenerative diseases. News about Alector often centers on its clinical trials, platform advances, and corporate decisions that shape the development of its pipeline.
Investors and followers of ALEC can use this news feed to track updates on latozinemab (AL001) for frontotemporal dementia due to GRN mutations, including the pivotal INFRONT-3 Phase 3 trial and subsequent decisions to discontinue extension studies after the trial did not meet its clinical co-primary endpoint. Coverage also includes developments in nivisnebart (AL101/GSK4527226), the PROGRESS-AD Phase 2 trial in early Alzheimer’s disease, and Alector’s collaboration with GSK around progranulin-elevating monoclonal antibodies.
Another recurring theme in Alector news is progress on the Alector Brain Carrier (ABC) blood-brain barrier platform and its ABC-enabled programs. Articles highlight preclinical candidates such as AL137, an anti-amyloid beta antibody for Alzheimer’s disease; AL050, a GCase enzyme replacement therapy for Parkinson’s disease; and siRNA programs like ADP064-ABC, ADP062-ABC, and ADP065-ABC targeting tau, alpha-synuclein, and NLRP3, respectively.
Corporate updates reported in press releases and 8-K filings include workforce reductions to align resources with strategic priorities, leadership transitions such as the appointment of Neil Berkley as Chief Financial Officer while continuing as Chief Business Officer, and participation in healthcare and CNS therapeutics conferences. Earnings releases and business updates provide additional context on collaboration revenue, research and development spending, and cash runway. Bookmark this page to follow how clinical data, platform progress, and corporate actions influence Alector’s trajectory in neurodegeneration.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET. The live webcast can be accessed on Alector's Investors page, with a replay available for 30 days post-event. Alector's approach targets immune dysfunction in neurodegenerative diseases, specifically in frontotemporal dementia and Alzheimer's disease, aiming to repair genetic mutations affecting the brain's immune response.